Press releases
- IGC Pharma to Attend BIO International Convention 2024
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
- IGC Pharma Adds Advisor in Artificial Intelligence
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
More ▼
Key statistics
On Wednesday, IGC Pharma Inc (IGS1:MUN) closed at 0.462, -31.56% below its 52-week high of 0.675, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.462 |
---|---|
High | 0.462 |
Low | 0.462 |
Bid | 0.472 |
Offer | 0.49 |
Previous close | 0.462 |
Average volume | 4.18k |
---|---|
Shares outstanding | 66.54m |
Free float | 39.12m |
P/E (TTM) | -- |
Market cap | 34.13m USD |
EPS (TTM) | -0.2479 USD |
Data delayed at least 15 minutes, as of May 22 2024 07:01 BST.
More ▼